Privia Health Group (PRVA) Stock Forecast & Price Target

$21.50 -0.95 (-4.23%)

(As of 11/26/2024 ET)

Privia Health Group - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 16 Analyst Ratings

Sell
0

Hold
2

Buy
14

Based on 16 Wall Street analysts who have issued ratings for Privia Health Group in the last 12 months, the stock has a consensus rating of "Buy." Out of the 16 analysts, 2 have given a hold rating, 12 have given a buy rating, and 2 have given a strong buy rating for PRVA.

Consensus Price Target

$25.07
16.59% Upside

According to the 16 analysts' twelve-month price targets for Privia Health Group, the average price target is $25.07. The highest price target for PRVA is $30.00, while the lowest price target for PRVA is $20.00. The average price target represents a forecasted upside of 16.59% from the current price of $21.50.

Get the Latest News and Ratings for PRVA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Privia Health Group and its competitors.

PRVA Analyst Ratings Over Time

Type	Current Forecast 11/27/23 to 11/26/24	1 Month Ago 10/28/23 to 10/27/24	3 Months Ago 8/29/23 to 8/28/24	1 Year Ago 11/27/22 to 11/27/23
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	12 Buy rating(s)	12 Buy rating(s)	12 Buy rating(s)	9 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$25.07	$24.73	$24.86	$34.64
Forecasted Upside	16.59% Upside	40.13% Upside	21.55% Upside	57.87% Upside
Consensus Rating	Buy	Buy	Moderate Buy	Buy

The Great AI-Energy Collision (Ad)

The biggest players in AI and tech are desperate to bring this limitless power source online. And fast. It’s the only way they can compete in their race for AI dominance. A handful of energy stocks are going to emerge from this transformation to dominate the sector.

Get the full story here, while you still can.

PRVA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

PRVA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Privia Health Group Stock vs. The Competition

Type	Privia Health Group	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.80	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	16.59% Upside	24,786.99% Upside	6.79% Upside
News Sentiment Rating	Positive News See Recent PRVA News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/8/2024	Barclays 3 of 5 stars		Boost Target	Equal Weight ➝ Equal Weight	$19.00 ➝ $21.00	-3.49%
11/8/2024	Truist Financial 2 of 5 stars		Boost Target	Buy ➝ Buy	$24.00 ➝ $27.00	+20.48%
10/11/2024	KeyCorp 3 of 5 stars		Initiated Coverage	Overweight	$23.00	+34.35%
8/26/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$23.00 ➝ $24.00	+15.05%
8/14/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$28.00 ➝ $28.00	+44.26%
7/9/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$23.00 ➝ $20.00	+18.69%
The Great AI-Energy Collision (Ad) The biggest players in AI and tech are desperate to bring this limitless power source online. And fast. It’s the only way they can compete in their race for AI dominance. A handful of energy stocks are going to emerge from this transformation to dominate the sector. Get the full story here, while you still can.
5/30/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Ha Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/10/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$37.00 ➝ $26.00	+44.36%
5/1/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$28.00 ➝ $24.00	+30.43%
4/22/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$25.00	+38.27%
3/6/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$38.00 ➝ $30.00	+41.38%
3/1/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$31.00 ➝ $29.00	+31.28%
3/1/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$30.00 ➝ $26.00	+16.49%
2/26/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$33.00 ➝ $25.00	+25.63%
2/22/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$27.00 ➝ $21.00	+2.79%
12/6/2023	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$27.00	+29.19%
5/5/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$39.00 ➝ $40.00	+38.70%
4/11/2023	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$33.00	+17.61%
3/7/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform	$41.00	+44.26%
2/3/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$32.00	+15.52%
1/9/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$45.00 ➝ $40.00	+85.96%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 07:38 PM ET.

PRVA Forecast - Frequently Asked Questions

: According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Privia Health Group is $25.07, with a high forecast of $30.00 and a low forecast of $20.00.
: 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Privia Health Group in the last year. There are currently 2 hold ratings, 12 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PRVA shares.
: According to analysts, Privia Health Group's stock has a predicted upside of 16.59% based on their 12-month stock forecasts.
: Over the previous 90 days, Privia Health Group's stock had 1 upgrade by analysts.
: Privia Health Group has been rated by research analysts at Barclays, KeyCorp, and Truist Financial in the past 90 days.
: Analysts like Privia Health Group more than other "medical" companies. The consensus rating for Privia Health Group is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how PRVA compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

The Great AI-Energy Collision (Ad)

Get the full story here, while you still can.

This page (NASDAQ:PRVA) was last updated on 11/26/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Privia Health Group (PRVA) Stock Forecast & Price Target